Brain Chemistry Labs, Institute for Ethnomedicine, Jackson, WY, 83001, USA.
Department of Chemistry, University of British Columbia, Okanagan, Kelowna, British Columbia, Canada.
Neurotox Res. 2018 Jan;33(1):184-191. doi: 10.1007/s12640-017-9744-7. Epub 2017 May 4.
β-N-Methylamino-L-alanine (BMAA) is a non-canonical amino acid implicated as a cause for amyotrophic lateral sclerosis/parkinsonism dementia complex and potentially other neurodegenerative diseases. As interest in this molecule has increased, there has been a proliferation of methods along with a plethora of opinions as to the superiority of some methods over others. We analyzed the literature with reference to BMAA and its naturally occurring isomers, N-(2-aminoethyl) glycine (AEG) and 2,4 diaminobutyric acid (DAB). A comparison of methods, results, and critiques reveal that a single method has been approved by the AOAC but several different methods provide comparable BMAA quantification concentrations in similar tissues. We also describe a productive way to move forward as technology improves and changes.
β-N-甲基氨基-L-丙氨酸(BMAA)是一种非典型氨基酸,被认为是肌萎缩侧索硬化/帕金森病痴呆症复合征的病因,并且可能是其他神经退行性疾病的病因。随着人们对这种分子的兴趣不断增加,各种方法层出不穷,对于某些方法优于其他方法的观点也层出不穷。我们参考了关于 BMAA 及其天然异构体 N-(2-氨基乙基)甘氨酸(AEG)和 2,4-二氨基丁酸(DAB)的文献。对方法、结果和评价的比较表明,虽然 AOAC 已经批准了一种方法,但其他几种方法在类似组织中也能提供可比的 BMAA 定量浓度。我们还描述了一种在技术改进和变化时向前推进的有效方法。